dc.contributor.author | Göschl, Lorenz | |
dc.contributor.author | Gmeiner, Günter | |
dc.contributor.author | Gärtner, Peter | |
dc.contributor.author | Stadler, Georg | |
dc.contributor.author | Enev, Valentin | |
dc.contributor.author | Thevis, Mario | |
dc.contributor.author | Schänzer, Wilhelm | |
dc.contributor.author | Guddat, Sven | |
dc.contributor.author | Forsdahl, Guro | |
dc.date.accessioned | 2021-10-22T12:55:16Z | |
dc.date.available | 2021-10-22T12:55:16Z | |
dc.date.issued | 2021-06-05 | |
dc.description.abstract | The exogenous anabolic-androgenic steroid (AAS) stanozolol stays one of the most detected substances in professional sports. Its detection is a fundamental part of doping analysis, and the analysis of this steroid has been intensively investigated for a long time. This contribution to the detection of stanozolol doping describes for the first time the unambiguous proof for the existence of 17-epistanozolol-1′N-glucuronide and 17-epistanozolol-2′N-glucuronide in stanozolol-positive human urine samples due to the access to high-quality reference standards. Examination of excretion study samples shows large detection windows for the phase-II metabolites stanozolol-1′N-glucuronide and 17-epistanozolol-1′N-glucuronide up to 12 days and respectively up to almost 28 days. In addition, we present appropriate validation parameters for the analysis of these metabolites using a fully automatic method online solid-phase extraction (SPE) method already published before. Limits of identification (LOIs) as low as 100 pg/ml and other validation parameters like accuracy, precision, sensitivity, robustness, and linearity are given. | en_US |
dc.identifier.citation | Göschl L, Gmeiner G, Gärtner P, Stadler, Enev, Thevis M, Schänzer W, Guddat, Forsdahl G. Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis. Drug Testing and Analysis. 2021;13(9):1668-1677 | en_US |
dc.identifier.cristinID | FRIDAID 1937395 | |
dc.identifier.doi | 10.1002/dta.3109 | |
dc.identifier.issn | 1942-7603 | |
dc.identifier.issn | 1942-7611 | |
dc.identifier.uri | https://hdl.handle.net/10037/22804 | |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | Göschl, L. (2022). Discovery and detection of phase-II metabolites of exogenous steroids in anti-doping analysis. (Doctoral thesis). <a href=https://hdl.handle.net/10037/24767>https://hdl.handle.net/10037/24767</a> | |
dc.relation.journal | Drug Testing and Analysis | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.subject | VDP::Social science: 200::Social science in sports: 330::Other subjects within physical education: 339 | en_US |
dc.subject | VDP::Samfunnsvitenskap: 200::Samfunnsvitenskapelige idrettsfag: 330::Andre idrettsfag: 339 | en_US |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728 | en_US |
dc.title | Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |